期刊文献+

环氧合酶-2抑制剂的三维定量构效关系研究 被引量:2

Three Dimensional Quantitative Structure-activity Relationship of Cyclooxygenase-2 Inhibitors
下载PDF
导出
摘要 建立三环系COX-1和COX-2抑制剂结构与活性的三维定量构效关系模型,为设计新型的具有选择性的COX-2抑制剂提供线索.通过与酶的对接并优化,确定化合物在受体结合腔中的构象,利用比较分子力场分析方法建立三维定量构效关系模型.模型1R_(cv)~2=0.685,最佳主成分数为6,传统相关系数为R^2=0.988,F=726.2,标准偏差S=0.080;模型2R_(cv)~2=0.573,最佳主成分数为6,传统相关系数为R^2=0.996,F=1147.6,标准偏差S=0.034.所得的模型不仅解释了化合物的构效关系,而且对预测集中的化合物有很好的预测能力;比较不同模型的系数相关图,分析了结构与活性、结构与选择性的关系,得到的结果可以指导新化合物的设计与合成. To quantitatively disclose the relationship between activity and structure, selectivity and structure of a series of tricyclic COX-2 inhibitors, 62 COX-2 inhibitors and 36 COX-1 inhibitors were got from literatures as a training set with the aim of developing a 3D QSAR activity-structure model using CoMFA. The conformation was confirmed using dock program and its energy was minimized using the methods of 'Stp dese' and 'Conj grad' with the force field 'MMFF94' in the energy gradient convergence 0.21 kJ.mol(-1). Both of CoMFA models yield good statistical significance, with R-ev(2) = 0.685, R-2 = 0.988, F = 726.2, S = 0.080 in the model of COX structure and R-ev(2) = 0.573, R-2 = 0.996, F = 1147.6, S = 0.034 in the model of COX-1. The low deviations of cv calculated values from the measured ones indicate powerful predictive ability of the models. The 3D QSAR explains the dependence of activity upon the structures of the compounds. Some structural information for designing new COX-2 inhibitors with higher activity and selectivity has been given.
出处 《化学学报》 SCIE CAS CSCD 北大核心 2003年第7期1114-1120,共7页 Acta Chimica Sinica
基金 国家自然科学基金(No.20072057)
关键词 环氧合酶-2抑制剂 三维定量构效关系 比较分子力场 非甾体类抗炎药 结构 活性构象 cyclooxygenase inhibitor CoMFA (comparative molecular field analysis) dock
  • 相关文献

参考文献14

  • 1Pong, S. S. ; Levine, L. J. Pharmacol. Exp. Ther. 1976,196, 226.
  • 2Allison, M. C. ; Howatson, A. G. ; Torrance, C. N. Engl. J.Med. 1992, 327, 749.
  • 3Fletcher, B. S. ; Kujubu, D. A. ; Perrin, D. M. ; Herschman,H. R. J. Biol. Chem. 1992, 267, 4338.
  • 4Kujubu, D. A. ; Fletcher, B. S. ; Vamum, B. C. J. Biol.Chem. 1991, 266(20), 12866.
  • 5The program sybyl 6.5 is availahle from Tripos Assoc., 1699 S.Hanley Rd., St. louis, MO 63144, 1998.
  • 6Puig, C.; Crespo, M. I.; Godessart, N. J. Med. Chem.2000, 43(2), 214.
  • 7Black, W. C. ; Brideau, C. ; Chan, C. C. J. Med. Chem.1999, 42(7), 1274.
  • 8Li, C. S. ; Black, W. C. ; Brideau, C. Bioorg. Med. Chem.Lett. 1999, 9(22), 3181.
  • 9Lau, C. K. ; Brideau, C. ; Chan, C. C. Bioorg. Med. Chem.Lett. 1999, 9(22), 3187.
  • 10Lei, X. S.; Zhu, Q. Q.; Qu, L. B.; Guo, Z. R. Acta Pharm.Sinica 1999, 34,590 (in Chinese).

同被引文献29

  • 1闵勇,易平,古昆,邱明华.1,5-二芳基吡唑类环氧合酶-1选择性抑制剂的CoMFA研究[J].云南大学学报(自然科学版),2005,27(5):429-433. 被引量:3
  • 2易平,闵勇,古昆,邱明华.硝基呋喃铵类化合物抗肺结核活性的CoMFA研究[J].云南大学学报(自然科学版),2006,28(1):54-59. 被引量:2
  • 3Fry DW. Inhibition of the epidermal growth factor receptor family of tyrosine kinases as an approach to cancer chemotherapy: progression from reversible to irreversible inhibitors.Pharmacol Ther, 1999, 82:207-218
  • 4Khazaie K, Schirrmacher V, Lichtner RB. EGF receptor in neoplasia and metastasis. Cancer Metastasis Rev, 1993, 12:255 -274
  • 5Wakeling AE, Barker A J, Davies DH, et al. New targets for therapeutic attack. Endocr Relat Cancer, 1997, 4:351-355
  • 6Noonberg SB, Benz CC. Tyrosine kinase inhibitors targeted to the epidermal growth factor receptor subfamily: role as anticancer agents. Drugs, 2000, 59(4):753-767
  • 7Stamos J, Sliwkowski MX, Eigenbrot C. Structure of the epidermal growth factor receptor kinase domain alone and in complex with a 4-anilinoquinazoline inhibitor. J Biol Chem,2002, 277(48):46265-46272
  • 8Wissner A, Berger DM, Boschelli DH, et al. 4-anilino-6,7-dialkoxyquinoline-3-carbonitrile inhibitors of epidermal growth factor receptor kinase and their bioisosteric relationship to the 4-anilino-6,7-dialk- oxyquinazoline inhibitors. J Med Chem,2000, 43(
  • 9Singh J, Dobrusin EM, Fry DW, et al. Structure-based design of a potent, selective, and irreversible inhibitor of the catalytic domain of the erbB receptor subfamily of protein tyrosine kinases. J Med Chem, 1997, 40(7):1130-1135
  • 10Drug Data Report. Prous JR. 2002, 24. Danvers: Prous Science, 2002

引证文献2

二级引证文献3

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部